Atea Pharmaceuticals (NASDAQ:AVIR) Director Sells 14,254 Shares of Stock

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report) Director Bruce Polsky sold 14,254 shares of the business’s stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $4.27, for a total value of $60,864.58. Following the transaction, the director directly owned 158,580 shares of the company’s stock, valued at $677,136.60. This represents a 8.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Bruce Polsky also recently made the following trade(s):

  • On Wednesday, November 18th, Bruce Polsky sold 18,252 shares of Atea Pharmaceuticals stock. The shares were sold at an average price of $3.95, for a total value of $72,095.40.
  • On Tuesday, November 17th, Bruce Polsky sold 8,720 shares of Atea Pharmaceuticals stock. The shares were sold at an average price of $4.03, for a total value of $35,141.60.

Atea Pharmaceuticals Trading Up 0.8%

AVIR traded up $0.03 during midday trading on Wednesday, reaching $3.99. The company’s stock had a trading volume of 342,250 shares, compared to its average volume of 307,434. The company has a fifty day simple moving average of $4.70 and a 200 day simple moving average of $4.94. The stock has a market cap of $320.40 million, a P/E ratio of -2.05 and a beta of 0.76. Atea Pharmaceuticals, Inc. has a twelve month low of $2.92 and a twelve month high of $6.45.

Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.11. Sell-side analysts expect that Atea Pharmaceuticals, Inc. will post -1.60 earnings per share for the current year.

Institutional Investors Weigh In On Atea Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc bought a new position in Atea Pharmaceuticals during the second quarter valued at about $33,000. Spark Investment Management LLC acquired a new position in Atea Pharmaceuticals in the 2nd quarter valued at approximately $75,000. Headlands Technologies LLC acquired a new position in Atea Pharmaceuticals in the 2nd quarter valued at approximately $77,000. Engineers Gate Manager LP acquired a new position in Atea Pharmaceuticals in the 2nd quarter valued at approximately $78,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Atea Pharmaceuticals in the 2nd quarter worth approximately $82,000. 86.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AVIR has been the topic of a number of research reports. Wall Street Zen raised shares of Atea Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atea Pharmaceuticals in a research note on Thursday, October 15th. Finally, Morgan Stanley increased their price target on shares of Atea Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $8.00.

View Our Latest Stock Report on Atea Pharmaceuticals

About Atea Pharmaceuticals

(Get Free Report)

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral diseases. Its research centers on compounds intended to interfere with viral replication. The company’s investigational portfolio has included bemnifosbuvir, an oral antiviral candidate studied for COVID-19, as well as programs targeting other viral infections, including dengue. These medicines are investigational and are not established marketed treatments.

Featured Articles

Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.